CR8258A - Derivados de azepine como agentes farmaceuticos - Google Patents

Derivados de azepine como agentes farmaceuticos

Info

Publication number
CR8258A
CR8258A CR8258A CR8258A CR8258A CR 8258 A CR8258 A CR 8258A CR 8258 A CR8258 A CR 8258A CR 8258 A CR8258 A CR 8258A CR 8258 A CR8258 A CR 8258A
Authority
CR
Costa Rica
Prior art keywords
azepine
derivatives
pharmaceutical agents
receptors
activity
Prior art date
Application number
CR8258A
Other languages
English (en)
Inventor
Martin Richard
Wang Tie-Lin
T Flatt Brenton
Gu Xiao-Hui
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR8258A publication Critical patent/CR8258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos, composiciones y metodos para modular la actividad de receptoresy para el tratamiento, prevencion, o mejora de uno o mas sintomas de una enfermedad o trastorno relacionado con la actividad de los receptores.
CR8258A 2003-07-23 2006-02-23 Derivados de azepine como agentes farmaceuticos CR8258A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
CR8258A true CR8258A (es) 2006-08-30

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8258A CR8258A (es) 2003-07-23 2006-02-23 Derivados de azepine como agentes farmaceuticos

Country Status (14)

Country Link
US (1) US8466143B2 (es)
EP (1) EP1648408A4 (es)
JP (1) JP4679517B2 (es)
KR (1) KR20060052867A (es)
CN (1) CN1852748A (es)
AU (1) AU2004259009A1 (es)
BR (1) BRPI0412262A (es)
CA (1) CA2532798C (es)
CR (1) CR8258A (es)
EC (1) ECSP066392A (es)
IL (1) IL173287A0 (es)
NO (1) NO20060871L (es)
RU (1) RU2006105646A (es)
WO (1) WO2005009387A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
BRPI0414541B8 (pt) 2003-09-17 2021-05-25 Janssen Pharmaceutica Nv compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
US20080161289A1 (en) 2005-03-14 2008-07-03 Glaxo Group Limited Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
AR073924A1 (es) * 2008-10-31 2010-12-09 Medivation Technologies Inc Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
CA2742320A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Pyrido[4,3-b]indoles containing rigid moieties
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
NZ596827A (en) 2009-05-22 2014-01-31 Abbott Lab Modulators of 5-ht receptors and methods of use thereof
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
JP5996528B2 (ja) * 2010-05-21 2016-09-21 アッヴィ・インコーポレイテッド ５−ｈｔ受容体調節物質およびその使用方法
WO2012112965A1 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
EP2675458A4 (en) 2011-02-18 2014-08-06 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
KR20170117020A (ko) * 2014-11-21 2017-10-20 아카나 테라퓨틱스, 엘티디. 질병의 치료를 위한 융합된 비시클릭 화합물
EP3237419B1 (en) 2014-12-22 2021-02-17 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN107912042A (zh) 2015-03-26 2018-04-13 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
SG11201810290WA (en) * 2016-05-25 2018-12-28 Akarna Therapeutics Ltd Combination therapies with farnesoid x receptor (fxr) modulators
EP3463372A4 (en) * 2016-05-25 2019-11-13 Akarna Therapeutics, Ltd. FUSIONED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
MA51679A (fr) 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
WO2019148036A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) * 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
EP1003751A1 (en) * 1997-08-04 2000-05-31 Amgen Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体

Also Published As

Publication number Publication date
EP1648408A1 (en) 2006-04-26
KR20060052867A (ko) 2006-05-19
JP2006528637A (ja) 2006-12-21
CA2532798A1 (en) 2005-02-03
US8466143B2 (en) 2013-06-18
US20070015746A1 (en) 2007-01-18
JP4679517B2 (ja) 2011-04-27
CN1852748A (zh) 2006-10-25
ECSP066392A (es) 2007-01-26
WO2005009387A3 (en) 2006-03-02
EP1648408A4 (en) 2006-11-29
IL173287A0 (en) 2006-06-11
BRPI0412262A (pt) 2006-09-19
NO20060871L (no) 2006-04-24
RU2006105646A (ru) 2007-09-10
WO2005009387A2 (en) 2005-02-03
CA2532798C (en) 2013-02-19
AU2004259009A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CR8258A (es) Derivados de azepine como agentes farmaceuticos
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
BRPI0513677B8 (pt) derivados de pirrol como agentes farmacêuticos
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
PA8591701A1 (es) Derivados de pirrolopirimidina
UY27939A1 (es) Compuestos
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
PA8680701A1 (es) Derivados de oxindol
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY28692A1 (es) Nuevos derivados de quinolina
ECSP088871A (es) Derivados de triazolopirazina
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CR10327A (es) "PIRIDIN(3-4-b) PIRAZINONAS"
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
ECSP077349A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
GT200500098A (es) Nuevos compuestos
GT200600114A (es) Derivados de ciclopropanocarboxamida
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CR8775A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200700096A (es) Compuestos de pirazolina
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)